Eli Lilly said Wednesday its combination antibody therapy "significantly" reduced COVID-19 deaths and hospitalizations in a phase 3 study.
In a study consisting of more than 750 high-risk patients with COVID-19, the company said a combination of bamlanivimab and etesevimab cut the risk of hospitalization and death by 87 percent, Reuters reports.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
-
Today's political cartoons - March 8, 2025Cartoons Saturday's cartoons - trade wars, healthcare costs, and more
-
Marbled tea eggs recipeThe Week Recommends With a beautiful exterior, these eggs are also marked by their soft yolk
-
The Washington Post: kowtowing to Trump?Talking Point The newspaper's opinion editor has handed in his notice following edict from Jeff Bezos
-
Texas outbreak brings 1st US measles death since 2015Speed read The outbreak is concentrated in a 'close-knit, undervaccinated' Mennonite community in rural Gaines County
-
Mystery illness spreading in Congo rapidly kills dozensSpeed Read The World Health Organization said 53 people have died in an outbreak that originated in a village where three children ate a bat carcass
-
Ozempic can curb alcohol cravings, study findsSpeed read Weight loss drugs like Ozempic and Wegovy may also be helpful in limiting alcohol consumption
-
New form of H5N1 bird flu found in US dairy cowsSpeed Read This new form of bird flu is different from the version that spread through herds in the last year
-
Microplastics accumulating in human brains, study findsSpeed Read The amount of tiny plastic particles found in human brains increased dramatically from 2016 to 2024
-
FDA approves painkiller said to thwart addictionSpeed Read Suzetrigine, being sold as Journavx, is the first new pharmaceutical pain treatment approved by the FDA in 20 years
-
Study finds possible alternative abortion pillSpeed Read An emergency contraception (morning-after) pill called Ella could be an alternative to mifepristone for abortions
-
California declares bird flu emergencySpeed Read The emergency came hours after the nation's first person with severe bird flu infection was hospitalized
